VidarabineCAS# 5536-17-4 |
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 5536-17-4 | SDF | Download SDF |
| PubChem ID | 21704 | Appearance | Powder |
| Formula | C10H13N5O4 | M.Wt | 267.24 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Synonyms | Ara-A; Arabinosyladenine; Adenine Arabinoside; 9-β-D-Arabinofuranosyladenine | ||
| Solubility | DMSO : 50 mg/mL (187.10 mM; Need ultrasonic) H2O : < 0.1 mg/mL (insoluble) | ||
| Chemical Name | (2R,3S,4S,5R)-2-(6-aminopurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol | ||
| SMILES | C1=NC2=C(C(=N1)N)N=CN2C3C(C(C(O3)CO)O)O | ||
| Standard InChIKey | OIRDTQYFTABQOQ-UHTZMRCNSA-N | ||
| Standard InChI | InChI=1S/C10H13N5O4/c11-8-5-9(13-2-12-8)15(3-14-5)10-7(18)6(17)4(1-16)19-10/h2-4,6-7,10,16-18H,1H2,(H2,11,12,13)/t4-,6-,7+,10-/m1/s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Vidarabine is an antiviral drug which is active against herpes simplex and varicella zoster viruses.
Target: DNA/RNA Synthesis
Vidarabine is a nucleoside antibiotic isolated from Streptomyces antibioticus. It has some antineoplastic properties and has broad spectrum activity against DNA viruses in cell cultures and significant antiviral activity against infections caused by a variety of viruses such as the herpes viruses, the vaccinia VIRUS and varicella zoster virus [1]. References: | |||||
Vidarabine Dilution Calculator
Vidarabine Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 3.742 mL | 18.7098 mL | 37.4195 mL | 74.8391 mL | 93.5489 mL |
| 5 mM | 0.7484 mL | 3.742 mL | 7.4839 mL | 14.9678 mL | 18.7098 mL |
| 10 mM | 0.3742 mL | 1.871 mL | 3.742 mL | 7.4839 mL | 9.3549 mL |
| 50 mM | 0.0748 mL | 0.3742 mL | 0.7484 mL | 1.4968 mL | 1.871 mL |
| 100 mM | 0.0374 mL | 0.1871 mL | 0.3742 mL | 0.7484 mL | 0.9355 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Vidarabine is an antiviral drug which is active against herpes simplex and varicella zoster viruses.
A nucleoside antibiotic isolated from Streptomyces antibioticus. It has some antineoplastic properties and has broad spectrum activity against DNA viruses in cell cultures and significant antiviral activity against infections caused by a variety of viruses such as the herpes viruses, the VACCINIA VIRUS and varicella zoster virus.
- Beclomethasone dipropionate
Catalog No.:BCC4257
CAS No.:5534-09-8
- Petasiphenone
Catalog No.:BCC8100
CAS No.:162616-81-1
- Soyasaponin II
Catalog No.:BCN1418
CAS No.:55319-36-3
- Atherosperminine
Catalog No.:BCN8208
CAS No.:5531-98-6
- Costunolide
Catalog No.:BCN5740
CAS No.:553-21-9
- Xanthyletin
Catalog No.:BCN6722
CAS No.:553-19-5
- Thonzonium Bromide
Catalog No.:BCC5636
CAS No.:553-08-2
- Tiamulin
Catalog No.:BCC9179
CAS No.:55297-95-5
- (Z)-Falcarindiol
Catalog No.:BCN8495
CAS No.:55297-87-5
- Atractylodin
Catalog No.:BCN6292
CAS No.:55290-63-6
- Praziquantel
Catalog No.:BCC4829
CAS No.:55268-74-1
- MnTBAP Chloride
Catalog No.:BCC6477
CAS No.:55266-18-7
- Baohuoside II
Catalog No.:BCN2888
CAS No.:55395-07-8
- Hydroxyisoleucine
Catalog No.:BCN8402
CAS No.:55399-93-4
- Lithium carbonate
Catalog No.:BCC7970
CAS No.:554-13-2
- Methazolamide
Catalog No.:BCC2318
CAS No.:554-57-4
- Deferasirox Fe3+ chelate
Catalog No.:BCC1521
CAS No.:554435-83-5
- 8beta-(4-Hydroxytigloyloxy)ovatifolin
Catalog No.:BCN7122
CAS No.:554449-27-3
- Boc- D-1-Nal-OH
Catalog No.:BCC3283
CAS No.:55447-00-2
- Anisodamine hydrobromide
Catalog No.:BCC8119
CAS No.:55449-49-5
- Z-Asp(OtBu)-OH.H2O
Catalog No.:BCC2789
CAS No.:5545-52-8
- Chimonanthine
Catalog No.:BCN7824
CAS No.:5545-89-1
- Jujuboside A
Catalog No.:BCN4949
CAS No.:55466-04-1
- Jujuboside B
Catalog No.:BCN4950
CAS No.:55466-05-2
Vidarabine, an Anti-Herpes Virus Agent, Protects Against the Development of Heart Failure With Relatively Mild Side-Effects on Cardiac Function in a Canine Model of Pacing-Induced Dilated Cardiomyopathy.[Pubmed:27818454]
Circ J. 2016 Nov 25;80(12):2496-2505.
BACKGROUND: In heart failure patients, chronic hyperactivation of sympathetic signaling is known to exacerbate cardiac dysfunction. In this study, the cardioprotective effect of Vidarabine, an anti-herpes virus agent, which we identified as a cardiac adenylyl cyclase inhibitor, in dogs with pacing-induced dilated cardiomyopathy (DCM) was evaluated. In addition, the adverse effects of Vidarabine on basal cardiac function was compared to those of the beta-blocker, carvedilol.Methods and Results:Vidarabine and carvedilol attenuated the development of pacing-induced systolic dysfunction significantly and with equal effectiveness. Both agents also inhibited the development of cardiac apoptosis and fibrosis and reduced the Na(+)-Ca(2+)exchanger-1 protein level in the heart. Importantly, carvedilol significantly enlarged the left ventricle and atrium; Vidarabine, in contrast, did not. Vidarabine-treated dogs maintained cardiac response to beta-AR stimulation better than carvedilol-treated dogs did. CONCLUSIONS: Vidarabine may protect against pacing-induced DCM with less suppression of basal cardiac function than carvedilol in a dog model. (Circ J 2016; 80: 2496-2505).
The use of online heart-cutting high-performance liquid chromatography coupled with linear ion trap mass spectrometry in the identification of impurities in vidarabine monophosphate.[Pubmed:28211639]
J Sep Sci. 2017 Apr;40(8):1674-1685.
It is difficult to identify unknown impurities in nucleotide analogues by mass spectrometry because mass-spectrometry-incompatible mobile phases need to be used to separate the major ingredient from impurities. In this study, Vidarabine monophosphate was selected, and unknown impurities were identified by online heart-cutting two-dimensional high-performance liquid chromatography and linear ion trap mass spectrometry. The one-dimensional reversed-phase column was filled with a mobile phase containing nonvolatile salt. In two-dimensional high-performance liquid chromatography, we used an Acclaim Q1 column with volatile salt, and the detection wavelength was 260 nm. The mass spectrum was scanned in positive- and negative-ion mode. The online heart-cutting and online demineralization technique ensured that the mobile phase was compatible with mass spectrometry; seven impurities were identified by MS(2) and MS(3) fragments. The mass fragmentation patterns of these impurities were investigated. The two isomers were semiprepared and complemented by nuclear magnetic resonance. The results were further compared with those of normal-phase high-performance liquid chromatography with mass spectrometry. The online heart-cutting two-dimensional high-performance liquid chromatography with mass spectrometry was superior in identifying more impurities. The method solves the problem of incompatibility between the mobile phase and mass spectrometry, so it is suitable for identifying unknown impurities. This method may also be used for investigating impurities in other nucleotide analogues.
Does Vidarabine Mediate Cardioprotection via Inhibition of AC5?[Pubmed:27402379]
J Pharmacol Exp Ther. 2016 Aug;358(2):242-3.
There is an ongoing discussion about the value of adenylyl cyclase 5 (AC5) as drug target for treatment of heart failure. This letter discusses statistical, pharmacokinetic, and pharmacodynamic reasons why the recently proposed cardioprotective effects of Vidarabine cannot be readily attributed to AC5 inhibition.
